The agreement grants Lupin the right to introduce Vonoprazan, an innovative treatment for Acid Peptic Disorders (APD), which include Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD)
Read More
The non-exclusive patent license agreement allows Mankind Pharma to commercialise Vonoprazan, a potassium-competitive acid blocker (P-CAB), for the treatment of Gastroesophageal Reflux Disease (GERD) and other acid-related disorders
Read More
